Survodutide
Also known as: BI 456906
Popular For
Weight loss, liver fat (NASH), metabolic health
Key Facts: Survodutide
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Phase 3 Clinical Trials - FDA Breakthrough Therapy Designation for MASH
- Administration
- Subcutaneous injection weekly
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- Human Trials
- Duration
- Long-term use expected
Mechanism of Action
Survodutide activates both GLP-1 receptors (appetite suppression, glucose control) and glucagon receptors (increased energy expenditure, reduced liver fat). The glucagon component adds metabolic benefits beyond pure GLP-1 agonists.
Research Summary
Phase 2 showed 83% of patients had MASH resolution vs 18% placebo. Phase 3 SYNCHRONIZE trials for obesity expected to complete early 2026. LIVERAGE trials for MASH enrolling 3,000+ participants.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Doses from clinical trials
Doses from Studies
Titrated up to 4.8mg weekly
Various dose levels studied
Duration
Long-term use expected
Administration
Subcutaneous injection weekly
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (55-75%)
- ●Vomiting (41%)
- ●Diarrhea (49%)
- ●Constipation
- ●GI effects during dose escalation
- ●Currently in Phase 3 trials
References
Related Peptides
Peptides commonly compared with Survodutide or used in similar applications.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Weight LossCagrilintide
Clinical TrialsA long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Weight LossSemaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossOrforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.
Weight LossCagriSema
Clinical TrialsA combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Weight LossLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on Survodutide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.